The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Did you read this?
https://www.fruitflowplus.com/COVID-19/
https://www.frontiersin.org/articles/10.3389/fnut.2020.583080/full
Cant say I know all the ins and outs but clinical trials of any significance cost money........
Lots of money.
But you are right, it would be good.
Hi Gixer,yes! i did think that...
but Aspirin (with potential known side effects-adding poss extra side issues to already otherwise weakened
immune systems)) are having a go.
Wouldnt it be prudent for ff (with no known side effects) to get on board?
Hi Tarka, the clue might be in the link you supplied as to why Fruitflow is not on a "Covid register"
As far as I am aware no clinical trials have been carried out on any benefits Fruitflow may have regarding Covid-19.
www.clinicaltrialsregister.eu
www.clinicaltrialregister.eu
Aspirin is on it!...proving its a blood thinning agent able to prevent covid patients blood
becoming sticky & thus potentially preventing neurological disability.....
Surely PXS should qualify to be on this register too (already proven ?)
As for who would want the IP?
3 possibilities maybe?
Not that I want to see it sold anytime soon.
everhopeful, he could only recommend what to do in a takeover situation but it would be down to a shareholder vote to decide.
Are you referring to the invisible man! Ford must be one of the most reclusive CEO's on AIM. He is not pictured anywhere and has never hosted a webcast or arranged a Q & A session as far as I am aware. He only seems to interact with his acolytes.
Why would they pay 5p when there is no competition ? who else wants PXS's IP ? Our useless CEO would take a TO at 2p imo.
5p is roughly 100m. Not a lot for the likes of by-health/DSM.
5p plus for me
I think most people would!
Cobalt,
I would bite your hand off at 2.2p!!!
Slam
My target is 22p.
PMSL . You'd need the biggest Chinese food / drink maker to put FF in several top sellers , not going to happen.
82k in 10 hours !!
Now at 82k views.
65k in 8 hours!
Views clicking up fast 62k in 7 hours
https://www.youtube.com/channel/UC7eJT2p2jN09lVP0BOgfdFg/videos?view=0&sort=dd
Attack my post and argue against it.
History will repeat here, so no need to talk much about it. Wondering why someone is wandering here who does not hold any pxs share. There must be some hidden agenda or just create some controversy by criticizing some well-informed post. Typical attention seeker.
Ca 22p would value the company at very approximately £400 million. To get anywhere near that, analysts would have to calculate a P/E ratio and that can't be done until a company begins to make a profit and shows earnings per share. Even using forward estimates would be tricky unless the company is prepared to estimate future earnings and Provexis have never released any information about potential profitability or plans to achieve that. In any case, this would be subjective and unreliable. I'm not saying that 22p is 100% unlikely but the company will have been taken out long before that and the income needed to justify a market capital of £400 million is a long way off IMO. if you move the decimal point one place to the left at 2.2p, then that is more likely if the Chinese adventure pays off!
sphinxy
spoke to IF - No, but from results......
Considering the success of previous fundraisings and the current performance of the business, the Directors have a reasonable expectation of raising sufficient additional capital to continue in operational existence for the foreseeable future and for this reason they continue to adopt the going concern basis in preparing the Group's and Parent Company's financial statements.
W$
My target is 22p. I am sure it will cross that. Please hold tight till it pass that limit.